SB202190

CHF 45.00
In stock
AG-CR1-0028-M0011 mgCHF 45.00
AG-CR1-0028-M0055 mgCHF 65.00
AG-CR1-0028-M02525 mgCHF 120.00
More Information
Product Details
Synonyms FHPI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole
Product Type Chemical
Properties
Formula C20H14FN3O
MW 331.3
CAS 152121-30-7
Purity Chemicals ≥97% (HPLC)
Appearance Off-white solid.
Solubility Soluble in methanol, DMSO or acetone; slightly soluble in ethyl acetate.
Identity Determined by 1H-NMR.
InChi Key QHKYPYXTTXKZST-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent and cell permeable p38 MAP kinase  inhibitor [1, 2].
  • Apoptosis inducer [3].
  • Inhibits p38α and β, but not γ and δ isoforms [4, 5].
  • Does not inhibit ERK2 or other members of the MAP kinase family or their upstream activators [6].
  • JNK activator [7].
  • Autophagic vacuole inducer [8]
Product References
  1. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis: J.C. Lee, et al.; Nature 372, 739 (1994)
  2. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes: C.L Manthey, et al.; J. Leukoc. Biol. 64, 409 (1998)
  3. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase: S. Nemoto, et al.; J. Biol. Chem. 273, 16415 (1998)
  4. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta): Y. Jiang, et al.; J. Biol. Chem. 271, 17920 (1996)
  5. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase: K.P. Wilson, et al.; Chem. Biol. 4, 423 (1997)
  6. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase: T. Fox, et al.; Protein Sci. 7, 2249 (1998)
  7. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism: H. Muniyappa & K.C. Das; Cell. Signal. 20, 675 (2008)
  8. SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition: MB. Menon, et al.; PLos One 6, e23054 (2011)
  9. A preliminary study on the proinflammatory mechanisms of Treponema pallidum outer membrane protein Tp92 in human macrophages and HMEC-1 cells: X. Luo, et al.; Microb. Pathog. 110, 176 (2017)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.